[EATG Global HIV News daily digest] Digest #25-2010

[EATG Global HIV News daily digest]

Global HIV News Daily Digest

Copied as fair use  -  Ana  -





Latest Headlines




  Gilead Quad pill may overtake Atripla, Milligan says 
  Pharma Industry Wednesday 10 February 2010
					
  
Gilead will begin three final-stage tests in 2010 for a four-drug
combination pill against HIV that has the potential to generate $4
billion a year by 2014. 
  SOURCE:
Bloomberg.com




  Uganda: Bill sets 10 yrs for spreading AIDS
  World Policy Wednesday 10 February 2010
					
  
A stringent bill on HIV/AIDS is expected to be presented before
Parliament this month. Under the HIV and AIDS Prevention and Control
Bill 2009, spreading the disease knowingly will become a criminal
offence.
  SOURCE:
The New Vision




  Medicines shortage prompts Government summit
  Access to treatment Wednesday 10 February 2010
					
  
The shortage of medicines as unscrupulous dealers take advantage of
cheap prices in Britain and then sell them abroad for profit has
prompted ministers to call a summit. 
  SOURCE:
Telegraph.co.uk




  OctoPlus
announces that Locteron interim Phase IIb data have been accepted for
oral and poster presentations at International Liver Congress in April
  Hepatitis Wednesday 10 February 2010
					
  
"We are delighted that the interim data for Locteron have been one of
few to be selected for an oral presentation at this prestigious
conference. We look forward to seeing the data and believe that this is
very good news for the future of Locteron."
  SOURCE:
OctoPlus N.V.




  Pharmasset reports smaller 1st-quarter loss after ending study of hepatitis B drug candidate
  Hepatitis Wednesday 10 February 2010
					
  
In April, Pharmasset ended development of a hepatitis drug candidate
called clevudine, citing side effects like muscle weakness. Clevudine
had been the company's most advanced drug candidate. 
  SOURCE:
CB Online




  Biolex announces Locteron® Phase 2b interim results in hepatitis C accepted for presentation at EASL Conference
  Hepatitis Wednesday 10 February 2010
					
  
Locteron, controlled-release interferon alpha 2b, is designed to
improve patient care by providing a more convenient once-every-two week
dosing schedule and by reducing the flu-like symptoms associated with
pegylated interferons, the current standard of care. 
  SOURCE:
Biolex Therapeutics, Inc.




  China publishes first-ever drug advice for doctors  
  Access to treatment Wednesday 10 February 2010
					
  
China’s Ministry of Health has published the country’s first-ever guidance for doctors on the use of medicines.
  SOURCE:
PharmaTimes




  HIV transmission in MSM pinned down
  MSM Wednesday 10 February 2010
					
  
HIV is transmitted -- at least among men who have sex with men -- by
the seminal plasma, rather than the seminal cells, researchers said.
  SOURCE:
MedPage Today




  HIV treatment success in everyday clinics is comparable to rates in clinical trials
  Treatment Wednesday 10 February 2010
					
  
People with HIV can achieve just as much benefit from treatment in “real world” clinics as they do in clinical trials.
  SOURCE:
AIDSmeds.com




  XDR TB emerging despite good adherence, due to sub-optimal treatment and bad infection control 
  Tuberculosis & Malaria Wednesday 10 February 2010
					
  
Extensively drug-resistant tuberculosis is most likely emerging as a
result of delays in diagnosis, sub-optimal treatment and poor infection
control, not failures in patient adherence, a newly published study of
XDR TB cases in a South African gold mine suggests. 
  SOURCE:
Aidsmap




  Even very low levels of pre-existing resistance increase risk of efavirenz failure 
  Treatment Wednesday 10 February 2010
					
  
The investigators used a testing technique called allele-specific PCR
testing, which can detect resistant virus that comprises below 0.1% of
the total viral population. 
  SOURCE:
Aidsmap


----------------------------------------------------
DISCLAIMER
The articles in this digest represent a diversity of opinions on topics
of interest to the HIV treatment activist community. The EATG is not
responsible for their content. The articles posted in this digest do
not necessarily reflect EATG views or opinions.
FAIR USE NOTICE
The digest may contain copyrighted material which has not always been
specifically authorised by the copyright owner. Such material is made
available for educational purposes to advance the understanding of
scientific, ethical, legal and social issues. It is believed that this
constitutes a 'fair use' of any such copyrighted material. This
material is distributed without profit.


 

Information in this digest was accurately quoted during its compilation.




      
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://mail.eatg.org/pipermail/eatg-forum_eatg.org/attachments/20100210/39ece927/attachment-0001.html>